Not logged inAssessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial
Middleton, G.; Liu, W.; Savage, J.; Bridgewater, J. A.; Ross, P.; Saunders, M. P.; Plummer, R.; Clive, S.; Coyle, V.; Thomas, A.; Taniere, P.; Billingham, L. .png)
Share.png)
SaveImpact of COVID-19 pandemic on clinical outcomes in hepatocellular carcinoma: A multicentre cohort studyDe Souza, S.; De Jong, J. Kahol; Jones, R.; Reeves, H.; Shetty, S.; Orr, J.; Bettinger, D.; Yip, V.; Temperley, L.; Geh, D.; Qurashi, M.; Allen, B.; Sturm, L.; Banerjee, A.; Ross, P.; Sharma, R. Share Save Clinical role of tumour markers in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus mFOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trialLamarca, A.; Palmer, D.; Wasan, H.; Ross, P.; Ma, Y. Ting; Arora, A.; Falk, S.; Gillmore, R.; Wadsley, J.; Patel, K.; Anthoney, A.; Maraveyas, A.; Waters, J.; Hoobs, C.; Macdonald, T.; Ryder, D.; Ramage, J.; Davies, L.; Bridgewater, J.; Valle, J. Share Save Share Save Share Save Share Save Share Save Share Save Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
